Trial Profile
Study for prevention of autoimmune non-insulin-dependent diabetes mellitus with sitagliptin (SPAN-S)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2018
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Pioglitazone
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SPAN-S
- 12 Oct 2018 Status changed from recruiting to completed.
- 01 Oct 2017 Results (n=14) published in the Diabetes Therapy.
- 16 Jun 2016 Planned End Date changed from 31 Dec 2020 to 31 Dec 2015.